eCommons@AKU
Department of Paediatrics and Child Health

Division of Woman and Child Health

7-1-2021

Vitamin D status and pulmonary exacerbations in children and
adolescents with cystic fibrosis: Experience from a tertiary care
center
Danish Abdul Aziz
Aga Khan University, danish.aziz@aku.edu

Syeda Khadija Fatima
Aga Khan University

Haissan Iftikhar
Aga Khan University, haissan.iftikhar@aku.edu

Fatima Mir
Aga Khan University, fatima.mir@aku.edu

Follow this and additional works at: https://ecommons.aku.edu/
pakistan_fhs_mc_women_childhealth_paediatr
Part of the Otolaryngology Commons, Pulmonology Commons, and the Respiratory Tract Diseases
Commons

Recommended Citation
Aziz, D. A., Fatima, S. K., Iftikhar, H., Mir, F. (2021). Vitamin D status and pulmonary exacerbations in
children and adolescents with cystic fibrosis: Experience from a tertiary care center. Lung India, 38(4),
326-329.
Available at: https://ecommons.aku.edu/pakistan_fhs_mc_women_childhealth_paediatr/1038

Original Article

Vitamin D status and pulmonary exacerbations in children
and adolescents with cystic fibrosis: Experience from a
tertiary care center
Danish Abdul Aziz1, Syeda Khadija Fatima1, Haissan Iftikhar2, Fatima Mir1
Department of Paediatrics and Child Health, Aga Khan University Hospital Karachi, Pakistan, 2Department of otorhinolaryngology,
Aga Khan University Hospital Karachi, Pakistan
1
Downloaded from http://journals.lww.com/lungindia by BhDMf5ePHKav1zEoum1tQfN4a+kJLhEZgbsIHo4XMi0hCywCX1AWnYQp/IlQrHD3i3D0OdRyi7TvSFl4Cf3VC4/OAVpDDa8K2+Ya6H515kE= on 08/25/2021

ABSTRACT
Background: The function of Vitamin D in preventing inflammation and infection has been studied previously for different
pathologies in different populations globally. Relationships between serum Vitamin D levels and its effect on pulmonary
exacerbations in the cystic fibrosis (CF) population are not well studied in our part of the world. Therefore, we aimed to
ascertain the Vitamin D status in pediatric and adolescent CF patients and its association with pulmonary exacerbations.
Materials and Methods: A retrospective study was conducted at The Aga Khan University Hospital from 2015 to 2018.
Patients of CF with sweat chloride value >60 mmol/l and who had at least one measurement of 25 hydroxy Vitamin D (25
OHD) were included in the study. Annual serum Vitamin D levels were documented for enrolled patients and their past
1‑year data were analyzed for pulmonary exacerbations, average length of stay, and tracheal/airway colonization with
organisms. Results: 69 patients were included in the study. 28 patients (40.57%) were found to be Vitamin D deficient,
22 patients (31.88%) were Vitamin D insufficient and 19 patients (27.53%) were labeled as Vitamin D insufficient. The
average number of exacerbations per year was significantly high in Vitamin D deficient group (3.71 ± 0.96) in comparison
with insufficient (3.18 ± 1.09) and sufficient groups (2.26 ± 0.93) (P < 0.001). Conclusion: Vitamin D deficiency is related
to an increased number of annual pulmonary exacerbations and pseudomonas infections.
KEY WORDS: 25‑hydroxyvitamin D (25‑OHD), cystic fibrosis, pseudomonas colonization, pulmonary exacerbations,
Vitamin D Deficiency
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INTRODUCTION
The cystic fibrosis (CF) patient population suffers from
Vitamin D deficiency due to inappropriate absorption
of fat‑soluble vitamins, reduced sunlight contact, and
decreased intake of Vitamin D‑enriched foods.[1] Recent
literature suggests Vitamin D has a great impact on
lung function and to combat pulmonary infections. [2]
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Additionally, to effects on bone health, there is mounting
evidence that Vitamin D plays a vital role in controlling
inflammation and maintaining balance in the immune
system.[3] Certain evidence suggests that deficiency in
Vitamin D results in an imbalance in pulmonary physiology
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and alters lung architecture.[4] Healthy infants and children
with a deficiency of Vitamin D have been documented
to have an increased risk of severe respiratory disease.[5]
The role of Vitamin D in the CF population is now well
recognized in literature and its deficiency is associated with
an increased risk of pulmonary exacerbations.[2] Pulmonary
functions and the lung’s ability to combat infections are
important predictors of mortality and morbidity in CF
patients and Vitamin D status in patients influences these
predictors.[6,7] Vitamin D deficiency prevalence is elevated
amongst neonates and children in South Asia.[8] Children
with CF in South Asia are usually diagnosed late and this
leads to higher morbidity and mortality.[9]
Serum Vitamin D levels and its effect on pulmonary
exacerbations are not well documented in our part of the
world. The objective of our study was to establish the
Vitamin D status in pediatric CF patients and determine
its association with pulmonary exacerbations, length of
stay (LOS) in hospital on average for each exacerbation,
and bacterial growth in tracheal cultures especially in
context to Pseudomonas aeruginosa. We hypothesize a
higher rate of pulmonary exacerbations amongst patients
with lower Vitamin D status.

MATERIALS AND METHODS
A retrospective study was conducted at The Aga Khan
University Hospital, Karachi, Pakistan. The study duration
was from January 2015 to December 2018. We selected
children and adolescents aged 3–18 years with CF, diagnosed
based on clinical features and sweat chloride value
of >60 mmol/L and who had at least one serum measurement
of 25 hydroxy Vitamin D (25 OHD) levels during the study
period. Patients were categorized into three groups, Vitamin
D sufficient, Vitamin D insufficient, and Vitamin D deficient
groups. CF Patients with serum 25 OHD concentrations < y
20 ng/ml were labeled as Vitamin D deficient, and those with
serum 25 OHD concentrations between 20 and 29.9 ng/ml
were categorized as Vitamin D insufficient, and patient with
serum 25 OHD concentrations ≥30 ng/ml were labeled as
Vitamin D sufficient.[2] Annual serum Vitamin D levels were
documented for every patient and their data for the past
1 year were analyzed for pulmonary exacerbations, average
LOS per admission, and colonization of trachea/airway with
bacteria specifically CF‑related organisms like P. aeruginosa
patients who had CF‑related hepatitis or pancreatitis were
excluded from the study.
Sweat was stimulated by means of pilocarpine iontophoresis
and sweat collection was done with Wescor® macroduct
sweat collection system as per hospital protocol. Total
patients with positive sweat chloride >60 mmol/L
were analyzed for Delta F‑508 genetic mutation. The
measurement of 25 hydroxy Vitamin D was done in the
hospital laboratory with a radioimmunoassay kit. These
data were retrieved from online patient records and
pharmacy profile.
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The fecal elastase test was not available for all patients
enrolled in the study; therefore, we included all patients
in our cohort irrespective of their pancreatic sufficiency
or insufficiency status. Pulmonary exacerbations in
CF patient was defined as “any hospitalization due to
respiratory function deterioration clinically observed as
increased cough frequency, increased sputum production,
increase work of breathing, and/or new crackles on
auscultation.”[10] Weight, height, sweat chloride value,
and Delta F‑508 mutation analysis were documented for
selected cases. Failure to thrive was defined as weight for
age below −2 SD on Z score. Short stature was defined
height or length less than two standard deviations for age
and gender (height for age <−2 Z‑score.).
Statistical analysis
Qualitative data were presented as frequencies and
percentages, whereas quantitative data were presented as
mean and standard deviation. The normality of the data
was checked using histograms and Kolmogorov–Smirnov
test and data were essentially normally distributed.
One‑way ANOVA was used to assess the difference in mean
values amongst the groups and Chi‑square test was used for
categorical data. The data were analyzed using IBM Corp.
Released 2011. IBM SPSS Statistics for Windows, Version
20.0. Armonk, NY: IBM Corp. P < 0.05 was considered
statistically significant.

RESULTS
A total of 97 CF patients were screened out of which
69 CF patients fulfilled the eligibility criteria within
the study duration. Male: female ratio was 1.47:1.
28 patients (40.57%) were found to be Vitamin D deficient,
22 patients (31.88%) were labeled as Vitamin D insufficient
whereas 19 patients (27.53%) were Vitamin D sufficient.
Frequencies of patients with failure to thrive and short
stature were similar between the three groups of patients
and not related to their Vitamin D status. Demographic
details of CF patients stratified on Vitamin D levels are
presented in Table 1.
Mean pulmonary exacerbations per year was significantly
high (3.71 ± 0.96) in Vitamin D deficient groups in
comparison with insufficient (3.18 ± 1.09) and sufficient
group (2.26 ± 0.93) P < 0.001. Figure 1 shows the
comparison of CF patients divided into three groups
according to the number of exacerbations/years with
Vitamin D status. Four age categories of patients were
defined from 3 years to 6 years, 7 years to 10 years,
11 years to 14 years, and 15 years to18 years. It was
noticed that the age of the patients had no linear
relationship with the average number of exacerbations/
year and patients in different age groups showed
varied frequencies of exacerbations/year Average LOS
per hospital admission did not show a significant
difference between the three groups (P = 0.16) [Table 2].
The frequency of pseudomonas infections showed a
327
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Table 1: Demographic details and laboratory features of cystic fibrosis population (n=69)
Patients, n (%)
Age (months)
Male: Female
Failure to thrive (weight for age−2SD), n (%)
Short stature (height less than−2SD), n (%)
Mean sweat chloride value (mmol/L)
Delta F‑508 mutation, n (%)
Mean serum 25‑OH Vitamin D value (ng/ml)

Vitamin D sufficient

Vitamin D insufficient

Vitamin D deficient

P

19 (27.53)
10.53±4.53
1.50
13 (68.42)
11 (57.89)
68.07±6.61
3 (15.78)
52.78±9.63

22 (31.88)
9.45±4.57
1.450
16 (72.72)
13 (59.09)
77.15±6.92
4 (18.18)
25.04±3.07

28 (40.57)
11.51±4.41
1.8
22 (78.57)
21 (75)
72.62±6.88
4 (14.28)
11.11±4.13

0.36
0.14
0.69
0.53
<0.05

SD: Standard deviation

Table 2: Average number of exacerbations, length of stay, and pseudomonas infection per year
Mean pulmonary exacerbations/year
Average length of stay/admission (days)
Pseudomonas infection, n (%)

Vitamin D sufficient (n=19)

Vitamin D insufficient (n=22)

Vitamin D deficient (n=28)

P

2.26±0.93
5.92±1.91
9 (47.36)

3.18±1.09
6.35±2.04
15 (68.18)

3.71±0.968
6.79±2.14
23 (82.14)

<0.001
0.16
0.043

pulmonary exacerbations were deficient in Vitamin D.[9]
Similarly, Vanstone et al. established depleted Vitamin
D status as a significant cause of developing pulmonary
exacerbations.[10] Regardless of patients receiving oral
supplementation of Vitamin D, the levels remained
low. Moreover, pulmonary bacterial colonization and
exacerbations were more prevalent in Vitamin D deficient
population.[11] 73% of children in our population failed
to thrive and approximately 60% of children had short
stature. There was no difference for these features among
the three categories according to Vitamin D status. This
indicates that nutritional status may not be an important
factor in defining Vitamin D statuses in children and
adolescents with CF.

Figure 1: Comparison of Vitamin D status and exacerbations/year in
different age categories

statistically significant difference between the three
groups (P = 0.043).

DISCUSSION
Our study highlights a significant association between
the status of Vitamin D in CF patients and pulmonary
exacerbations. 40.57% of patients were Vitamin D deficient
and 31.88% patients were Vitamin D insufficient. The
average number of exacerbations per year was significantly
high in Vitamin D deficient group (3.71 ± 0.968)
compared to insufficient and sufficient groups (P < 0.001).
Average LOS per admission for CF patients showed no
major differences between the groups (P = 0.16) and
pseudomonas growth in tracheal swab/sputum cultures
showed significant differences (P = 0.043).
In our study, CF patients have Vitamin D levels <30 ng/ml.
Yadav et al. showed that majority of patients in their cohort
had Vitamin D deficiency with almost all patients who had
328

Pulmonary exacerbations in CF children have a negative
impact on pulmonary functions resulting in the poor quality
of life and higher mortality.[12‑14] In our study, it is evident
that the average events of pulmonary exacerbations in the
group with Vitamin D deficiency were significantly high
in comparison with Vitamin D insufficient and Vitamin
D sufficient groups. Our results concur with previously
published reports, which showed a substantial increase
in the number of exacerbations in patients with Vitamin
D deficiency and insufficiency.[2,6,15] Protection from viral
infections is stated in most studies as a major mechanism
of Vitamin D in pulmonary protection.[16] There are strong
data suggesting Vitamin D supplementation during
inflammation resulting in the reduction of inflammatory
marker interleukin‑8 and improved forced vital capacity,
suggesting an anti‑inflammatory role.[17]
Pseudomonas airway colonization has a great impact on
lung function, and it is one of the important factors that
determine the morbidity and mortality in such patients.[18]
Previously it has been shown that children with Vitamin D
insufficiency have a higher tendency to be colonized with
P. aeruginosa. This explains facilitating role of Vitamin D
in preventing airway infections and long‑standing lung
function in CF.[18] Similarly, studies show that Vitamin D
plays a role in controlling influential antimicrobial peptide
Lung India • Volume 38 • Issue 4 • July-August 2021
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LL‑37. LL‑37 has a strong action against P. aeruginosa and it
was hypothesized that the surplus of bacterial colonization
predominantly P. aeruginosa in Vitamin‑D deficient
subjects may be the cause of decreased production of
LL‑37, Vitamin D increases levels LL‑37 promoting the
innate immunity.[19] In our study, we found that Vitamin D
deficient group has an increased number of patients with
pseudomonas colonization in comparison with insufficient
and sufficient groups (P = 0.043).
The limitation of our study includes the inability to
determine the exocrine pancreatic status of the patients
due to limited excess for all patients for fecal elastase test
during the study period. Pancreatic enzymes help in the
absorption of fat‑soluble vitamins including Vitamin D and
have a strong link with the respiratory health and nutrition
of these patients.[20] We also did not determine pulmonary
function tests at the time of exacerbations in these patients
due to the nonavailability of the facility.

3.
4.
5.
6.
7.
8.
9.
10.
11.

CONCLUSION
12.

Our study supports the current recommendation for annual
screening of fat‑soluble vitamin levels especially levels
of Vitamin D in all patients with CF. Additionally, the
association between Vitamin D deficiency with pulmonary
exacerbation and P. aeruginosa colonization deserves
further prospective design research in order to determine
more definitively the influence of Vitamin D deficiency on
inflammation, infection, and clinical outcomes.
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